Mitral transcatheter edge-to-edge repair: A state of art and strategic principles_Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Authors：

PAN Wenzhi , LONG Yuliang ,  ZHOU Daxin ,  GE Junbo

Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, National Clinical Research Center for Interventional Medicine, Shanghai, 200032, P. R. China;

Corresponding author：

ZHOU Daxin, Email: zhou.daxin@zs-hospital.sh.cn; GE Junbo, Email: jbge@zs-hospital.sh.cn

Keywords：

Mitral regurgitation; transcatheter edge-to-edge repair; intervention technology

DOI：

10.7507/1007-4848.202311008

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Transcatheter edge-to-edge repair (TEER) for mitral regurgitation (MR) is known as M-TEER. Its strengths include: precise targets and fewer implants; simple and clear principles for catheterization; originating from dependable medical concepts and broad applicability. Furthermore, TEER offers advantages in real-time hemodynamic and effectiveness measurement throughout the procedure over surgical edge-to-edge repair (SEER). When it comes to patients with degenerative mitral regurgitation , M-TEER should aim to deliver more optimum procedural outcomes. In functional mitral regurgitation, a modest transvalvular gradients or moderate residual shunt can be tolerated with M-TEER, which reduces the risk of problems and has no bearing on the patient's prognosis.

Citation： PAN Wenzhi, LONG Yuliang, ZHOU Daxin, GE Junbo. Mitral transcatheter edge-to-edge repair: A state of art and strategic principles. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2024, 31(2): 181-185. doi: 10.7507/1007-4848.202311008 Copy

1.	Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: Executive summary: A report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. J Am Coll Cardiol, 2021, 77(4): 450-500.
2.	Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J, 2022, 43(7): 561-632.
3.	Ruf TF, Hahn RT, Kreidel F, et al. Short-term clinical outcomes of transcatheter tricuspid valve repair with the third-generation MitraClip XTR system. JACC Cardiovasc Interv, 2021, 14(11): 1231-1240.
4.	Aurich M, Volz MJ, Mereles D, et al. Initial experience with the PASCAL ace implant system for treatment of severe tricuspid regurgitation. Circ Cardiovasc Interv, 2021, 14(9): e010770.
5.	潘文志, 龙愉良, 周达新, 等. 经导管缘对缘修复: 定义、分类及技术更新. 中国介入心脏病学杂志, 2022, 30(6): 440-444.
6.	Ives CW, Prejean SP, Vardas PN, et al. Initial experiences with the MitraClip G4: Review of the novel device features. Innovations (Phila), 2021, 16(5): 448-455.
7.	Long Y, Pan W, Pan C, et al. Real-time echocardiographic guidance for transcatheter repair noncentral mitral regurgitation using the novel ValveClamp system. J Card Surg, 2021, 36(11): 4378-4380.
8.	Lim DS, Kar S, Spargias K, et al. Transcatheter valve repair for patients with mitral regurgitation: 30-day results of the CLASP sudy. JACC Cardiovasc Interv, 2019, 12(14): 1369-1378.
9.	Maisano F, Torracca L, Oppizzi M, et al . The edge-to-edge technique: A simplified method to correct mitral insufficiency. Eur J Cardiothorac Surg, 1998, 13(3): 240-246.
10.	Makhdoum A, Dokollari A, Elbatarny M, et al. Resurgence of the edge-to-edge repair of the mitral valve. Curr Opin Cardiol, 2021, 36(2): 125-129.
11.	Sharma A, Agrawal S, Goel S, et al. Surgical treatment of ischemic mitral regurgitation: Valve repair versus replacement. Curr Cardiol Rep, 2017, 19(1): 3.
12.	De Bonis M, Lapenna E, Taramasso M, et al. Very long-term durability of the edge-to-edge repair for isolated anterior mitral leaflet prolapse: Up to 21 years of clinical and echocardiographic results. J Thorac Cardiovasc Surg, 2014, 148(5): 2027-2032.
13.	De Bonis M, Lapenna E, Maisano F, et al. Long-term results (≤18 years) of the edge-to-edge mitral valve repair without annuloplasty in degenerative mitral regurgitation: Implications for the percutaneous approach. Circulation, 2014, 130(11 Suppl 1): S19-S24.
14.	Mack MJ, Lindenfeld J, Abraham WT, et al. 3-year outcomes of transcatheter mitral valve repair in patients with heart failure. J Am Coll Cardiol, 2021, 77(8): 1029-1040.
15.	Oh NA, Kampaktsis PN, Gallo M, et al. An updated meta-analysis of MitraClip versus surgery for mitral regurgitation. Ann Cardiothorac Surg, 2021, 10(1): 1-14.
16.	金沁纯, 潘文志, 周达新. 经导管缘对缘修复治疗房性功能性二尖瓣反流的进展更新. 心电与循环, 2023, 42(4): 310-314, 340.
17.	Aranda-Domene R, Canovas SJ. Going further of mitral ring annuloplasty: The role of surgery in atrial functional mitral regurgitation. J Thorac Dis, 2023, 15(5): 2381-2384.
18.	Luk A, Butany J, Ahn E, et al. Mitral repair with the Evalve MitraClip device: Histopathologic findings in the porcine model. Cardiovasc Pathol, 2009, 18(5): 279-285.
19.	St Goar FG, Fann JI, Komtebedde J, et al. Endovascular edge-to-edge mitral valve repair: Short-term results in a porcine model. Circulation, 2003, 108(16): 1990-1993.
20.	Ladich E, Michaels MB, Jones RM, et al. Pathological healing response of explanted MitraClip devices. Circulation, 2011, 123(13): 1418-1427.
21.	Nardi P, Pellegrino A, Olevano C, et al. Mitral valve repair for the treatment of degenerative mitral valve disease with or without prosthetic ring annuloplasty: Long-term outcomes. J Cardiovasc Surg (Torino), 2013, 54(2): 305-312.
22.	Sugiura A, Kavsur R, Spieker M, et al. Recurrent mitral regurgitation after mitraclip: Predictive factors, morphology, and clinical implication. Circ Cardiovasc Interv, 2022, 15(3): e010895.
23.	Hassan A, Eleid MF. Recurrent mitral regurgitation after MitraClip: Defining success and predicting outcomes. Circ Cardiovasc Interv, 2022, 15(3): e011837.
24.	Adamo M, Pagnesi M, Popolo Rubbio A, et al. Predictors of optimal procedural result after transcatheter edge-to-edge mitral valve repair in secondary mitral regurgitation. Catheter Cardiovasc Interv, 2022, 99(5): 1626-1635.
25.	El-Shurafa H, Arafat AA, Albabtain MA, et al. Residual versus recurrent mitral regurgitation after transcatheter mitral valve edge-to-edge repair. J Card Surg, 2021, 36(6): 1904-1909.
26.	Suri RM, Clavel MA, Schaff HV, et al. Effect of recurrent mitral regurgitation following degenerative mitral valve repair: Long-term analysis of competing outcomes. J Am Coll Cardiol, 2016, 67(5): 488-498.
27.	Sato H, Cavalcante JL, Bae R, et al. Coaptation reserve predicts optimal reduction in mitral regurgitation and long-term survival with transcatheter edge-to-edge repair. Circ Cardiovasc Interv, 2022, 15(7): e011562.
28.	Koell B, Ludwig S, Weimann J, et al. Long-term outcomes of patients with elevated mitral valve pressure gradient after mitral valve edge-to-edge repair. JACC Cardiovasc Interv, 2022, 15(9): 922-934.
29.	Makkar RR, Chikwe J, Chakravarty T, et al. Transcatheter mitral valve repair for degenerative mitral regurgitation. JAMA, 2023, 329(20): 1778-1788.
30.	Kar S, Mack MJ, Lindenfeld J, et al. Relationship between residual mitral regurgitation and clinical and quality-of-life outcomes after transcatheter and medical treatments in heart failure: COAPT Trial. Circulation, 2021, 144(6): 426-437.
31.	Halaby R, Herrmann HC, Gertz ZM, et al. Effect of mitral valve gradient after mitraclip on outcomes in secondary mitral regurgitation: Results From the COAPT Trial. JACC Cardiovasc Interv, 2021, 14(8): 879-889.
32.	Higuchi S, Orban M, Stolz L, et al . Impact of Residual mitral regurgitation on survival after transcatheter edge-to-edge repair for secondary mitral regurgitation. JACC Cardiovasc Interv, 2021, 14(11): 1243-1253.

1. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: Executive summary: A report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. J Am Coll Cardiol, 2021, 77(4): 450-500.
2. Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J, 2022, 43(7): 561-632.
3. Ruf TF, Hahn RT, Kreidel F, et al. Short-term clinical outcomes of transcatheter tricuspid valve repair with the third-generation MitraClip XTR system. JACC Cardiovasc Interv, 2021, 14(11): 1231-1240.
4. Aurich M, Volz MJ, Mereles D, et al. Initial experience with the PASCAL ace implant system for treatment of severe tricuspid regurgitation. Circ Cardiovasc Interv, 2021, 14(9): e010770.
5. 潘文志, 龙愉良, 周达新, 等. 经导管缘对缘修复: 定义、分类及技术更新. 中国介入心脏病学杂志, 2022, 30(6): 440-444.
6. Ives CW, Prejean SP, Vardas PN, et al. Initial experiences with the MitraClip G4: Review of the novel device features. Innovations (Phila), 2021, 16(5): 448-455.
7. Long Y, Pan W, Pan C, et al. Real-time echocardiographic guidance for transcatheter repair noncentral mitral regurgitation using the novel ValveClamp system. J Card Surg, 2021, 36(11): 4378-4380.
8. Lim DS, Kar S, Spargias K, et al. Transcatheter valve repair for patients with mitral regurgitation: 30-day results of the CLASP sudy. JACC Cardiovasc Interv, 2019, 12(14): 1369-1378.
9. Maisano F, Torracca L, Oppizzi M, et al . The edge-to-edge technique: A simplified method to correct mitral insufficiency. Eur J Cardiothorac Surg, 1998, 13(3): 240-246.
10. Makhdoum A, Dokollari A, Elbatarny M, et al. Resurgence of the edge-to-edge repair of the mitral valve. Curr Opin Cardiol, 2021, 36(2): 125-129.
11. Sharma A, Agrawal S, Goel S, et al. Surgical treatment of ischemic mitral regurgitation: Valve repair versus replacement. Curr Cardiol Rep, 2017, 19(1): 3.
12. De Bonis M, Lapenna E, Taramasso M, et al. Very long-term durability of the edge-to-edge repair for isolated anterior mitral leaflet prolapse: Up to 21 years of clinical and echocardiographic results. J Thorac Cardiovasc Surg, 2014, 148(5): 2027-2032.
13. De Bonis M, Lapenna E, Maisano F, et al. Long-term results (≤18 years) of the edge-to-edge mitral valve repair without annuloplasty in degenerative mitral regurgitation: Implications for the percutaneous approach. Circulation, 2014, 130(11 Suppl 1): S19-S24.
14. Mack MJ, Lindenfeld J, Abraham WT, et al. 3-year outcomes of transcatheter mitral valve repair in patients with heart failure. J Am Coll Cardiol, 2021, 77(8): 1029-1040.
15. Oh NA, Kampaktsis PN, Gallo M, et al. An updated meta-analysis of MitraClip versus surgery for mitral regurgitation. Ann Cardiothorac Surg, 2021, 10(1): 1-14.
16. 金沁纯, 潘文志, 周达新. 经导管缘对缘修复治疗房性功能性二尖瓣反流的进展更新. 心电与循环, 2023, 42(4): 310-314, 340.
17. Aranda-Domene R, Canovas SJ. Going further of mitral ring annuloplasty: The role of surgery in atrial functional mitral regurgitation. J Thorac Dis, 2023, 15(5): 2381-2384.
18. Luk A, Butany J, Ahn E, et al. Mitral repair with the Evalve MitraClip device: Histopathologic findings in the porcine model. Cardiovasc Pathol, 2009, 18(5): 279-285.
19. St Goar FG, Fann JI, Komtebedde J, et al. Endovascular edge-to-edge mitral valve repair: Short-term results in a porcine model. Circulation, 2003, 108(16): 1990-1993.
20. Ladich E, Michaels MB, Jones RM, et al. Pathological healing response of explanted MitraClip devices. Circulation, 2011, 123(13): 1418-1427.
21. Nardi P, Pellegrino A, Olevano C, et al. Mitral valve repair for the treatment of degenerative mitral valve disease with or without prosthetic ring annuloplasty: Long-term outcomes. J Cardiovasc Surg (Torino), 2013, 54(2): 305-312.
22. Sugiura A, Kavsur R, Spieker M, et al. Recurrent mitral regurgitation after mitraclip: Predictive factors, morphology, and clinical implication. Circ Cardiovasc Interv, 2022, 15(3): e010895.
23. Hassan A, Eleid MF. Recurrent mitral regurgitation after MitraClip: Defining success and predicting outcomes. Circ Cardiovasc Interv, 2022, 15(3): e011837.
24. Adamo M, Pagnesi M, Popolo Rubbio A, et al. Predictors of optimal procedural result after transcatheter edge-to-edge mitral valve repair in secondary mitral regurgitation. Catheter Cardiovasc Interv, 2022, 99(5): 1626-1635.
25. El-Shurafa H, Arafat AA, Albabtain MA, et al. Residual versus recurrent mitral regurgitation after transcatheter mitral valve edge-to-edge repair. J Card Surg, 2021, 36(6): 1904-1909.
26. Suri RM, Clavel MA, Schaff HV, et al. Effect of recurrent mitral regurgitation following degenerative mitral valve repair: Long-term analysis of competing outcomes. J Am Coll Cardiol, 2016, 67(5): 488-498.
27. Sato H, Cavalcante JL, Bae R, et al. Coaptation reserve predicts optimal reduction in mitral regurgitation and long-term survival with transcatheter edge-to-edge repair. Circ Cardiovasc Interv, 2022, 15(7): e011562.
28. Koell B, Ludwig S, Weimann J, et al. Long-term outcomes of patients with elevated mitral valve pressure gradient after mitral valve edge-to-edge repair. JACC Cardiovasc Interv, 2022, 15(9): 922-934.
29. Makkar RR, Chikwe J, Chakravarty T, et al. Transcatheter mitral valve repair for degenerative mitral regurgitation. JAMA, 2023, 329(20): 1778-1788.
30. Kar S, Mack MJ, Lindenfeld J, et al. Relationship between residual mitral regurgitation and clinical and quality-of-life outcomes after transcatheter and medical treatments in heart failure: COAPT Trial. Circulation, 2021, 144(6): 426-437.
31. Halaby R, Herrmann HC, Gertz ZM, et al. Effect of mitral valve gradient after mitraclip on outcomes in secondary mitral regurgitation: Results From the COAPT Trial. JACC Cardiovasc Interv, 2021, 14(8): 879-889.
32. Higuchi S, Orban M, Stolz L, et al . Impact of Residual mitral regurgitation on survival after transcatheter edge-to-edge repair for secondary mitral regurgitation. JACC Cardiovasc Interv, 2021, 14(11): 1243-1253.

Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Mitral transcatheter edge-to-edge repair: A state of art and strategic principles

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content